Hernández PM, Narro FME

Language: Spanish
References: 8
Page: 43-45
PDF size: 204.34 Kb.

REFERENCES

1. Bénet T, Sánchez-Picot V, Messaoudi M, Chou M, Eap T, Wang J et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017; 65 (4): 604-612. doi: 10.1093/cid/cix378.

2. Meissner HC. Respiratory syncytial virus. In: Long SS, Prober CG, Fischer M, editors. Principles and practice of pediatric infectious diseases. 6th ed. Philadelphia: Elsevier; 2023. p. 1185.

3. American Academy of Pediatrics. Respiratory syncytial virus. In: Red book: 2024-2027 report of the Committee on Infectious Diseases. 33rd ed. Itasca, IL: AAP; 2024. pp. 713-721.

4. Ortiz IFJ, González SN, Arias GE, Castillo BJI, Gutiérrez TIF, Laris GA et al. Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP): prevención de la infección por virus sincitial respiratorio en México, 2024. Rev Latin Infect Pediatr. 2024; 37 (s1): s6-s28.

5. Arias GE, Otero MF, Acosta RRA. Virus sincitial respiratorio. El camino a la prevención. Rev Latin Infect Pediatr. 2024; 37 (2): 63-66. doi: 10.35366/117221.

6. Hsiao A, Hansen J, Fireman B, Timbol J, Zerbo O, Mari K et al. Effectiveness of nirsevimab against RSV and RSV-related events in infants. Pediatrics. 2025; 156 (2): e2024069510. doi: 10.1542/peds.2024-069510.

7. Centers for Disease Control and Prevention (CDC). Clesrovimab (MK-1654): pediatric clinical program [presentación en reunión del Advisory Committee on Immunization Practices (ACIP), 23-24 de octubre de 2024]. Atlanta, GA: CDC; 2024. Disponible en: https://www.cdc.gov/acip/downloads/slides-2024-10-23-24/02-rsv-mat-peds-sinha-508.pdf

8. Jenco M. FDA approves new monoclonal antibody to protect infants from RSV. AAP News [Internet]. 2025. Available in: https://publications.aap.org/aapnews/news/32373/FDA-approves-new-monoclonal-antibody-to-protect?autologincheck=redirected